Elsevier

Immunology Letters

Volume 215, November 2019, Pages 1-11
Immunology Letters

Review
Vaccine platforms for the prevention of Lassa fever

https://doi.org/10.1016/j.imlet.2019.03.008Get rights and content
Under a Creative Commons license
open access

Highlights

  • The epidemiological significance of Lassa fever in West Africa is discussed.

  • Viral ecology, pathology, and immunobiology of Lassa virus infection is described.

  • Multiple vaccine candidates have been tested in pre-clinical models.

  • Lassa fever vaccine candidates have yet to progress to clinical trials.

  • Five platform technologies have been selected for expedited development.

Abstract

Lassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), which is endemic throughout much of West Africa. The virus primarily circulates in the Mastomys natalensis reservoir and is transmitted to humans through contact with infectious rodents or their secretions; human-to-human transmission is documented as well. With the exception of Dengue fever, LASV has the highest human impact of any haemorrhagic fever virus. On-going outbreaks in Nigeria have resulted in unprecedented mortality. Consequently, the World Health Organization (WHO) has listed LASV as a high priority pathogen for the development of treatments and prophylactics. Currently, there are no licensed vaccines to protect against LASV infection. Although numerous candidates have demonstrated efficacy in animal models, to date, only a single candidate has advanced to clinical trials. Lassa fever vaccine development efforts have been hindered by the high cost of biocontainment requirements, the absence of established correlates of protection, and uncertainty regarding the extent to which animal models are predictive of vaccine efficacy in humans. This review briefly discusses the epidemiology and biology of LASV infection and highlights recent progress in vaccine development.

Keywords

Lassa fever
Lassa virus
Vaccine
T cells
Antibodies
Viral vector

Cited by (0)